DM-CHOC-PEN for Brain Tumors in AYA Subjects

Completed · Phase 2

Conditions studied: Advanced Cancer, Brain Metastases

In brief

4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood brain barrier (BBB), ability to localize in intracranial tumor tissue, lacks neurotoxicity and not transported out of the brain via Pgp (p-glycoprotein). DM-CHOC-PEN has completed a Phase I Adolescent and Young Adult (AYA) trial in humans, some of which possessed primary and secondary tumors involving the brain. Complete remissions in both primary (astrocytoma, GBM) and metastatic lung cancers were reported. This Phase II trial is closed for adolescent and young adults (AYA) subjects with advanced cancer - brain involvement is required.

Key facts

Study ID
NCT03668847
Run by
DEKK-TEC, Inc.
People needed
20
Starts
2019-01-01
Expected to finish
2021-09-30
Last updated by the study team
2022-11-08

Who can join

Age: 15 and older, up to 39. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.